MX2021011286A - Compuestos de heterociclil(fenil)metanol útiles en el tratamiento de la hiperglucemia. - Google Patents

Compuestos de heterociclil(fenil)metanol útiles en el tratamiento de la hiperglucemia.

Info

Publication number
MX2021011286A
MX2021011286A MX2021011286A MX2021011286A MX2021011286A MX 2021011286 A MX2021011286 A MX 2021011286A MX 2021011286 A MX2021011286 A MX 2021011286A MX 2021011286 A MX2021011286 A MX 2021011286A MX 2021011286 A MX2021011286 A MX 2021011286A
Authority
MX
Mexico
Prior art keywords
hyperglycaemia
heterocyclyl
phenyl
treatment
compounds useful
Prior art date
Application number
MX2021011286A
Other languages
English (en)
Spanish (es)
Inventor
Benjamin Pelcman
Tore Bengtsson
Original Assignee
Atrogi Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atrogi Ab filed Critical Atrogi Ab
Publication of MX2021011286A publication Critical patent/MX2021011286A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/54—Spiro-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
MX2021011286A 2019-03-20 2020-03-20 Compuestos de heterociclil(fenil)metanol útiles en el tratamiento de la hiperglucemia. MX2021011286A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1903827.2A GB201903827D0 (en) 2019-03-20 2019-03-20 New compounds and methods
PCT/GB2020/050762 WO2020188301A1 (en) 2019-03-20 2020-03-20 Heterocyclyl(phenyl)methanol compounds useful in the treatment of hyperglycaemia

Publications (1)

Publication Number Publication Date
MX2021011286A true MX2021011286A (es) 2022-01-24

Family

ID=66381053

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011286A MX2021011286A (es) 2019-03-20 2020-03-20 Compuestos de heterociclil(fenil)metanol útiles en el tratamiento de la hiperglucemia.

Country Status (13)

Country Link
US (1) US20220152004A1 (cg-RX-API-DMAC7.html)
EP (1) EP3941468A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022525795A (cg-RX-API-DMAC7.html)
KR (1) KR20210141622A (cg-RX-API-DMAC7.html)
CN (1) CN113784953A (cg-RX-API-DMAC7.html)
AU (1) AU2020243426A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021018578A2 (cg-RX-API-DMAC7.html)
CA (1) CA3133768A1 (cg-RX-API-DMAC7.html)
GB (1) GB201903827D0 (cg-RX-API-DMAC7.html)
IL (1) IL286432A (cg-RX-API-DMAC7.html)
MX (1) MX2021011286A (cg-RX-API-DMAC7.html)
TW (1) TWI846843B (cg-RX-API-DMAC7.html)
WO (1) WO2020188301A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714740D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201903832D0 (en) 2019-03-20 2019-05-01 Atrogi Ab New compounds and methods
GB202204085D0 (en) * 2022-03-23 2022-05-04 Atrogi Ab New compounds and methods

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985887A (en) * 1973-10-19 1976-10-12 Smithkline Corporation 3-Substituted-4-hydroxyphenyl-2-piperidylcarbinols as β-adrenergic stimulants
US3910933A (en) * 1973-10-19 1975-10-07 Smithkline Corp 3-Substituted-4-hydroxyphenyl-2-piperidylcarbinols
ZA756740B (en) * 1974-10-30 1976-10-27 Scherico Ltd Azacyclic compounds
FR2436779A1 (fr) * 1978-09-22 1980-04-18 Pharmindustrie Derives de pyrrolidine-2 methanol utilisables comme medicaments
FR2460929A1 (fr) * 1979-07-06 1981-01-30 Roussel Uclaf Nouveaux derives de l'a-phenyl 2-pyrrolidinemethanol et leur sels, procede de preparation, application a titre de medicaments et compositions les renfermant
EP0128120A3 (de) * 1983-06-02 1985-11-13 Ciba-Geigy Ag Trisubstituierte Oxazolidinone
JP2002518301A (ja) * 1998-06-18 2002-06-25 ノバルテイス・アクチエンゲゼルシヤフト 寄生虫を寄せ付けないための組成物
PT1087660E (pt) * 1998-06-18 2002-11-29 Novartis Ag Formulacoes para repelir vermina
EP1786410A2 (en) * 2004-09-07 2007-05-23 Sosei R&D Ltd. The treatment of inflammatory disorders and pain
GB0419828D0 (en) * 2004-09-07 2004-10-13 Arakis Ltd The treatment of inflammatroy disorders and pain
GB2435979A (en) * 2006-03-07 2007-09-12 Helen Theresa Haywood Door intercom telephone device
FR2917735B1 (fr) * 2007-06-21 2009-09-04 Sanofi Aventis Sa Nouveaux indazoles substitutes, leur preparation et leur utilisation en therapeutique
GB201714740D0 (en) * 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses

Also Published As

Publication number Publication date
US20220152004A1 (en) 2022-05-19
BR112021018578A2 (pt) 2021-11-23
GB201903827D0 (en) 2019-05-01
TWI846843B (zh) 2024-07-01
CN113784953A (zh) 2021-12-10
CA3133768A1 (en) 2020-09-24
EP3941468A1 (en) 2022-01-26
AU2020243426A1 (en) 2021-11-04
JP2022525795A (ja) 2022-05-19
IL286432A (en) 2021-10-31
KR20210141622A (ko) 2021-11-23
WO2020188301A1 (en) 2020-09-24
TW202102473A (zh) 2021-01-16

Similar Documents

Publication Publication Date Title
EP4616912A3 (en) Phosphoalkyl ribose polymers comprising biologically active compounds
MX2021000795A (es) Compuestos heterociclicos para inhibir la actividad de shp2.
PH12021550045A1 (en) 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
MX2020002824A (es) Aminas beta-hidroxi heterociclicas y su uso en el tratamiento de la hiperglucemia.
MX2021011374A (es) Compuestos de heteroaril(heterocyclil)metanol útiles en el tratamiento de la hiperglucemia.
EP4566612A3 (en) Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
ZA202206923B (en) New methylquinazolinone derivatives
GEAP202215535A (en) Compounds
MX2020002825A (es) Beta-hidroxietilaminas heteroaril sustituidas para su uso en el tratamiento de hiperglucemia.
MX2025008327A (es) Composiciones y metodos para el tratamiento de trastornos del snc
WO2021011713A8 (en) Imidazopyrimidines as eed inhibitors and the use thereof
EA200601619A1 (ru) 5,6-диалкил-7-амино-триазолопиримидины, способ их получения и их применение для борьбы с патогенными грибами, а также содержащие их средства
MX2009012418A (es) Derivados de quinazolin-oxima como inhibidores de hsp90.
ZA202213152B (en) Novel acid secretion inhibitor and use thereof
GEP20156368B (en) Non-nucleoside reverse transcriptase inhibitors
WO2007084728A3 (en) 2-imino-benzimidazoles
WO2019178191A8 (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glycopyranosidase inhibitors
WO2021079196A3 (en) Mettl3 modulators
MX2024009177A (es) Compuestos y metodos de uso
PH12021552513A1 (en) Pyrrole compounds
MX2021003232A (es) Inhibidores de o-glicoproteina-2-acetamido-2-desoxi-3-d-glucopiran osidasa.
MX2020000576A (es) Compuestos quimicos.
MX385203B (es) Compuestos y métodos para tratar infecciones bacterianas.
MX2024008868A (es) Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso.
MX2025002166A (es) Compuestos y metodos para modular her2